Ardelyx - ARDX Stock Forecast, Price & News

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Analysts Set New Price Targets

ARDX has been the topic of several research analyst reports. Cantor Fitzgerald cut Ardelyx from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $7.00 to $1.00 in a research note on Friday, May 6th. StockNews.com lowered Ardelyx from a "hold" rating to a "sell" rating in a research report on Saturday, August 6th. Piper Sandler reduced their target price on shares of Ardelyx from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 18th. Finally, Wedbush reissued a "neutral" rating on shares of Ardelyx in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $4.83.

Ardelyx Trading Up 3.9 %

NASDAQ:ARDX traded up $0.03 on Friday, reaching $0.93. 1,991,414 shares of the stock traded hands, compared to its average volume of 1,563,752. The company has a market capitalization of $143.66 million, a price-to-earnings ratio of -0.82 and a beta of 1.84. Ardelyx has a 12 month low of $0.49 and a 12 month high of $1.92. The company's fifty day simple moving average is $0.68 and its 200 day simple moving average is $0.78.

Ardelyx (NASDAQ:ARDX - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting analysts' consensus estimates of ($0.19). Ardelyx had a negative net margin of 2,594.88% and a negative return on equity of 191.74%. During the same quarter in the previous year, the business earned ($0.45) EPS. Equities analysts anticipate that Ardelyx will post -0.7 EPS for the current fiscal year.

Insider Activity

In other news, insider Susan Rodriguez sold 43,920 shares of Ardelyx stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $0.65, for a total value of $28,548.00. Following the completion of the sale, the insider now directly owns 289,593 shares in the company, valued at $188,235.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Michael Raab sold 103,624 shares of the company's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $0.65, for a total transaction of $67,355.60. Following the completion of the sale, the chief executive officer now owns 668,826 shares in the company, valued at $434,736.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Susan Rodriguez sold 43,920 shares of the firm's stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $0.65, for a total value of $28,548.00. Following the completion of the transaction, the insider now directly owns 289,593 shares in the company, valued at $188,235.45. The disclosure for this sale can be found here. Insiders have sold a total of 235,185 shares of company stock valued at $153,157 over the last ninety days. 6.00% of the stock is currently owned by corporate insiders.